Fiscal Year: May - April
Medtronic plc (MDT), listed on the NYSE, has a market capitalization of $101.92B. As of Jul 01, 2026, the stock is trading at $79.62 per share@else an unavailable price , offering investors a clear view of its current market value. Medtronic plc is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 20.97, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Medtronic plc also offers a dividend yield of 3.57%, making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for Medtronic plc (MDT). The fair value estimate will be displayed once sufficient analyst forecast data is collected.
The proprietary SS Score for Medtronic plc is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Medtronic plc, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Medtronic plc is 18.46, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Medtronic plc (MDT) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Medtronic plc (MDT) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Medtronic plc (MDT) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Medtronic plc. To access the full SS Score, consider upgrading your subscription.
Medtronic plc is a significant player in the industry sector, with a market capitalization of $101.92B and a competitive P/E ratio of 20.97. Investors should compare these metrics with industry peers to gauge whether Medtronic plc is outperforming or underperforming within its sector.
Medtronic offers high growth potential in addition to discounted valuation.
Acquisition delivers simplicity and access, supporting physicians across the full procedural workflow GALWAY, Ireland, June 12, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healt...
BofA lowered the firm’s price target on Medtronic (MDT) to $95 from $110 and keeps a Buy rating on the shares. Noting that the firm’s services team continues to highlight…
Tech stocks are pulling back, and healthcare is surging.
Goldman Sachs analyst David Roman lowered the firm’s price target on Medtronic (MDT) to $83 from $84 and keeps a Neutral rating on the shares. The company’s Q4 results carried…
Bernstein analyst Lee Hambright lowered the firm’s price target on Medtronic (MDT) to $97 from $112 and keeps an Outperform rating on the shares following a solid Q4. After weaker…
Truist lowered the firm’s price target on Medtronic (MDT) to $86 from $95 and keeps a Hold rating on the shares. The company delivered a Q4 organic revenue beat but…
Baird analyst David Rescott lowered the firm’s price target on Medtronic (MDT) to $85 from $93 and keeps a Neutral rating on the shares. The firm updated its model following…
UBS analyst Priya Sachdeva lowered the firm’s price target on Medtronic (MDT) to $85 from $90 and keeps a Neutral rating on the shares. Medtronic’s solid Q4 results and seemingly…
Meeting to be held in Los Angeles on June 10-11 hosted by Piper Sandler.
BTIG upgraded Medtronic (MDT) to Buy from Neutral with a $90 price target Medtronic has demonstrated consistent mid-single digit organic growth the past several quarters and the trajectory is improvin...
BTIG upgraded Medtronic (MDT) to Buy from Neutral.
Stifel analyst Rick Wise lowered the firm’s price target on Medtronic (MDT) to $80 from $95 and keeps a Hold rating on the shares. Medtronic’s Affera pulsed-field-ablation technology continues to…
Needham analyst Mike Matson lowered the firm’s price target on Medtronic (MDT) to $101 from $120 and keeps a Buy rating on the shares. The company’s Q4 revenue and EPS…
Says with robotics penetration still in high-single digits, sees significant runway ahead. Says expects foreign exchange to be neutral to roughly $100M headwind in FY27. Says expects FY27 tariff impac...
Stock futures are slightly lower while investors digest stronger-than-expected employment data and wait for Friday’s official nonfarm payrolls report. According to ADP, private-sector employers added ...
The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts' estimates.
Medtronic said its profit and sales rose during its fiscal fourth quarter, reflecting steps the company has taken to improve business performance and drive growth.
Company also announces 510(k) pending for LigaSure™ RAS Maryland instrument on the Hugo RAS system, and 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for use in robotic-assis...
Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of techno...
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.
